New Market Perspective
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

New Market Perspective

Investing

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

by admin September 23, 2024
September 23, 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now recorded confirmed partial responses (PRs) out of 16 assessed at the four-month timepoint, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

HIGHLIGHTS

Six (6) patients in the Company’s ACCENT trial in pancreatic cancer have now achieved the required reduction in tumour size with no detection of new lesionsThe ACCENT trial can now proceed to recruit the next cohort of 24 patients, giving a total of 50 patients on studyThe ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients

The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period.

A total of 50 patients are planned for the Phase 2a ACCENT trial. With the six (6) confirmed PRs now obtained, recruitment of the remaining 24 patients in the trial will begin at the existing open trial sites in Australia and South Korea. Recruitment of the second cohort of patients is expected to be completed by end of Q1 2025.

A detailed interim analysis of the Phase 2a trial data obtained to date will be reported in the coming weeks; however, key points are noted below:

Narmafotinib continues to be generally well tolerated by patients with no safety trends identified or dose reductions recorded to dateIn addition to 6 confirmed PRs, there have been 7 patients who have recorded stable disease over 2 or more months, including one patient whose stable disease has improved to achieve a partial response at their 4-month assessment

Amplia CEO and MD Dr Chris Burns commented: “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial’

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Global AI Safety Network to Address Opportunities and Challenges at Inaugural Meeting
next post
Mike Johnson says Harris is Iran’s ‘preferred candidate,’ demands info on Trump campaign hacks

Related Posts

Quimbaya Gold Completes Final Payment on Four Tahami...

March 13, 2025

+30,000m Drilling Program to Commence Across Brightstar’s Enlarged...

May 6, 2024

Inside Billionaire Gina Rinehart’s Key Mining Investments

August 15, 2024

Chinese Market Approval for WOA’s Lupin Protein Isolate

February 25, 2025

SilverCrest Metals: Gold, Silver vs. Fiat — We...

May 31, 2024

Cannabis Round-Up: Banking Reform and Rescheduling De-Prioritized as...

February 5, 2025

Top 5 Canadian Mining Stocks This Week: O3...

December 14, 2024

Hydrogen Stocks: 9 Biggest Companies

February 21, 2024

Willem Middelkoop: Gold to Benefit as Chaos Rises,...

March 12, 2025

China Approves 11 Nuclear Reactors in US$31 Billion...

August 21, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • UK police make second arrest in connection with fires linked to PM Starmer

      May 18, 2025
    • Deported mom says toddler’s return to Venezuela after separation by US authorities was a ‘miracle’

      May 18, 2025
    • Duterte scores landslide win in local elections. But can he be mayor from The Hague?

      May 18, 2025
    • Austria’s JJ wins Eurovision 2025 with ‘Wasted Love’

      May 18, 2025
    • How Pope Leo dealt with years of abuse allegations in a powerful Catholic society in Peru

      May 18, 2025
    • The popemobile, a signet ring and a ‘betrothal:’ How Pope Leo’s inauguration will unfold

      May 18, 2025

    Popular

    • 1

      10 Top Oil-producing Countries (Updated 2024)

      October 19, 2024
    • 2

      Powered by rain, this seed carrier could help reforest the most remote areas

      December 19, 2023
    • 3

      A troubling theory about traders profiting from Hamas’ attack on Israel drew much attention. Why it may not be so simple.

      December 13, 2023
    • 4

      Americans are starting to feel better about the economy and inflation

      December 13, 2023
    • 5

      Rare Earths Stocks: 8 Biggest Companies in 2024

      January 12, 2024
    • 6

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024
    • 7

      Investing in Graphene Companies

      May 9, 2024

    Categories

    • Business (1,322)
    • Investing (3,124)
    • Politics (4,105)
    • World (4,057)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: newmarketperspective.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 newmarketperspective.com | All Rights Reserved